Late-Stage Colon and Gastrointestinal Cancers

The indication includes colon, pancreatic, gastric, appendiceal, esophageal, small bowel, anal, and rectal cancers.

RapidSelection™ is also available through a no-cost, nationwide clinical study, and other financial assistance is available.

For late-stage patients and their oncologists
looking for effective treatments now

Colon and Gastrointestinal cancers are particularly challenging diseases that often go undetected until they reach an advanced stage. For those grappling with late-stage colon and GI cancers, standard treatments like surgery, chemotherapy, and targeted therapy may have limited effectiveness.

Late-stage cancer patients have typically failed all of the highly effective drugs given to earlier patients. They are then faced with a long list of less effective drugs, typically with population response rates of around 20%.

For each patient, it's very likely that, “hidden” within that long list of low-effectiveness drugs, a few drugs will be highly effective for that unique patient.

RapidSelection™ has solved this problem by directly testing a late-stage patient's live cancer cells against long lists of drugs to find any personalized, effective drugs.

RapidSelection™ is available in two versions

EarlyAccess

RapidSelection™ EarlyAccess measures live cancer cells against a predetermined panel of 20 FDA-approved cancer drugs.

This option requires that you share the treatment outcome data to help Travera build additional clinical evidence.

Turnaround time: 2 days from sample collection
Total drugs tested: 20 FDA-approved
Sample types: Tissue, Malignant Fluids

OpenPanel

RapidSelection™ OpenPanel measures live cancer cells against a panel of up to 20 FDA-approved cancer drugs of your choice.

Our catalog includes over 100 FDA-approved drugs.

Turnaround time: 2 days from sample collection
Total drugs tested: up to 20 FDA-approved
Sample types: Tissue, Malignant Fluids

Drug panel for testing with RapidSelection™ EarlyAccess: Colon and Gastrointestinal Cancers

NCCN Inhibitors

Encorafenib (Braftovi), Entrectinib (Rozlytrek), Lapatinib (Tykerb), Larotrectinib (Vitrakvi), Regorafenib (Stivarga).

NCCN Chemotherapies

FOLFIRI, FOLFOX, Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Tipiracil (Lonsurf).

Off-label Inhibitors

Binimetinib (Mektovi), Dasatinib (Sprycel), Everolimus (Afinitor), Imatinib (Gleevec), Olaparib (Lynparza), Ponatinib (Iclusig), Sunitinib (Sutent), Trametinib (Mekinist), Vincristine (Oncovin), Vandetanib (Caprelsa).

Step 1
Order

Discuss the RapidSelection™ Test with your patient. You can contact Travera’s clinical support services to determine which testing option to prescribe.

Step 2
Sample Collection

We will ship a sample collection kit to the person indicated in the test requisition form. Once collected, the sample will reach our lab quickly via overnight shipping.

Step 3
Test results

Within the following 2 days, the test results are ready to review online or via fax. Our clinical support services are available to answer any questions.

Please reach out to us anytime and we will respond within 24 hours.

Thank you, we have received your request and will be in touch shortly.

Something went wrong while submitting the form.
Please try again.

Contact details

RapidSelection™
by Travera, Inc.

200 Boston Ave, Suite 1500
Medford, MA 02155
United States

Phone

781-874-0808

Late-Stage Colon and Gastrointestinal Cancers

For late-stage patients and their oncologists
looking for effective treatments now

RapidSelection™ is available in two versions

Drug panel for testing with RapidSelection™ EarlyAccess: Colon and Gastrointestinal Cancers

How it works

Contact us

Late-Stage Colon and Gastrointestinal Cancers

For late-stage patients and their oncologistslooking for effective treatments now

RapidSelection™ is available in two versions

Drug panel for testing with RapidSelection™ EarlyAccess: Colon and Gastrointestinal Cancers

How it works

Contact us

For late-stage patients and their oncologists
looking for effective treatments now